Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

BackgroundRight- (R) and left-sided (L) metastatic colorectal cancer (mCRC) exhibit different clinical and molecular features. Several retrospective analyses showed that survival benefit of anti-EGFR-based therapy is limited to RAS/BRAF wt L-sided mCRC patients. Few data are available about third-li...

Full description

Bibliographic Details
Main Authors: Lisa Salvatore, Maria Bensi, Raffaella Vivolo, Ina Valeria Zurlo, Emanuela Dell’Aquila, Roberta Grande, Annunziato Anghelone, Alessandra Emiliani, Fabrizio Citarella, Maria Alessandra Calegari, Marta Ribelli, Michele Basso, Carmelo Pozzo, Giampaolo Tortora
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
primary tumor site
third-line therapy
RAS/BRAF wild-type
anti-egfr ab
Regorafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1125013/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1125013/full

Similar Items